Health Care • Biotechnology: Commercial Physical & Biological Resarch
$23.83 ▲ +0.34
(+1.45%)
MKT CAP: $519.6M • VOL: 86.2K
52W L $12 52W H $24
NRC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $137.4M | $143.1M | $148.6M |
| YoY Revenue Growth % | -4.0% | -3.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $22.6M | $35.2M | $40.0M |
| Operating Margin % | 16.4% | 24.6% | 27.0% |
| Net Income (GAAP) | $11.6M | $24.8M | $31.0M |
| EBITDA (Normalized) | $31.2M | $47.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $26.4M | $34.6M | $38.1M |
| Capital Expenditures (CapEx) | $10.7M | $15.4M | — |
| Free Cash Flow (FCF) | $15.7M | $19.2M | $38.1M |
| FCF Margin % | 11.5% | 13.4% | 25.7% |
| Return on Invested Capital (ROIC %) | 21.0% | 32.7% | — |
| Cash & Short-Term Equivalents | $4.1M | $4.2M | — |
| Total Debt (Short + Long Term) | $75.0M | $57.9M | — |
| Total Stockholders' Equity | $14.0M | $31.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NRC.